These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 2892456)

  • 21. Effect of long-term ketanserin treatment on 5-HT levels, platelet aggregation and peripheral circulation in patients with Raynaud's phenomenon. A double-blind, placebo-controlled cross-over study.
    Arneklo-Nobin B; Elmér O; Akesson A
    Int Angiol; 1988; 7(1):19-25. PubMed ID: 3290356
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Management of pulmonary circulation alterations].
    Quero Jiménez MC; Burgueros Valero M; González Dieguez C; Domínguez Pérez F; Pinto Corraliza J; Rodríguez Fernández M
    Rev Esp Cardiol; 1993; 46 Suppl 2():13-28. PubMed ID: 7905203
    [No Abstract]   [Full Text] [Related]  

  • 23. [New treatments for Raynaud's syndrome].
    Bellucci S; Kedra W; Ajzenberg N; Tobelem G; Caen J
    Nouv Rev Fr Hematol (1978); 1988; 30(1-2):103-7. PubMed ID: 3290833
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Management of Raynaud's phenomenon].
    Boccalon H; Monin A; Reggy M
    Soins Cardiol; 1986 Apr; (38):27-9. PubMed ID: 3637023
    [No Abstract]   [Full Text] [Related]  

  • 25. Ketanserin versus nifedipine in secondary Raynaud's phenomenon.
    Kirch W; Linder HR; Hutt HJ; Ohnhaus EE; Mahler F
    Vasa; 1987; 16(1):77-80. PubMed ID: 3554811
    [No Abstract]   [Full Text] [Related]  

  • 26. Treatment of Raynaud's phenomenon.
    García-Carrasco M; Jiménez-Hernández M; Escárcega RO; Mendoza-Pinto C; Pardo-Santos R; Levy R; Maldonado CG; Chávez GP; Cervera R
    Autoimmun Rev; 2008 Oct; 8(1):62-8. PubMed ID: 18692160
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [The therapy of Raynaud's phenomenon].
    Di Giacinto G
    Clin Ter; 1993 Feb; 142(2):161-74. PubMed ID: 8472530
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Does serotonin receptor blockade have a therapeutic effect in Raynaud's phenomenon?
    Brouwer RM; Wenting GJ; Visser W; Schalekamp MA
    Vasa Suppl; 1987; 18():64-7. PubMed ID: 3299817
    [No Abstract]   [Full Text] [Related]  

  • 29. [Treatment of Raynaud's phenomenon with alpha-lytic agents].
    Clément DL
    Rev Med Liege; 1980 Oct; 35(19):650-2. PubMed ID: 6109369
    [No Abstract]   [Full Text] [Related]  

  • 30. New prospects for the treatment of Raynaud's phenomenon using a serotoninergic S2 receptor antagonist (ketanserin) and stable derivatives of prostacyclin.
    Pola P; Tondi P; Serricchio M; Favuzzi A; Gerardino L
    Angiology; 1993 Feb; 44(2):123-8. PubMed ID: 8434805
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of chronic ketanserin treatment on serotonin-induced platelet aggregation in patients with Raynaud's phenomenon.
    Marasini B; Biondi ML; Mollica R
    Eur J Clin Pharmacol; 1990; 39(3):289-90. PubMed ID: 2257869
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Treatment of Raynaud's syndrome with calcium entry blockers].
    Shcherbakov AB; Guseva NG; Mach ES
    Ter Arkh; 1987; 59(4):89-92. PubMed ID: 3296288
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [How I treat...Raynaud's phenomenon].
    Piérard GE
    Rev Med Liege; 1998 Mar; 53(3):119-20. PubMed ID: 9594609
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hypertensive patients with Raynaud's phenomenon or intermittent claudication and their treatment with ketanserin.
    van Oene JC
    Drugs; 1988; 36 Suppl 1():148-51. PubMed ID: 3240729
    [No Abstract]   [Full Text] [Related]  

  • 35. Calcium-channel blockers for Raynaud's phenomenon in systemic sclerosis.
    Thompson AE; Shea B; Welch V; Fenlon D; Pope JE
    Arthritis Rheum; 2001 Aug; 44(8):1841-7. PubMed ID: 11508437
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Raynaud's phenomenon.
    O'connor CM
    J Vasc Nurs; 2001 Sep; 19(3):87-92; quiz 93-4. PubMed ID: 11533581
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment for Raynaud's: beyond calcium channel blockers.
    Bergstrom KG; Perelman RO
    J Drugs Dermatol; 2008 May; 7(5):497-500. PubMed ID: 18505148
    [No Abstract]   [Full Text] [Related]  

  • 38. [Treatment of Raynaud's syndrome with ketanserin. Clinical, biological and hemodynamic aspects].
    Bellucci S; Kedra AW; Naccache-Herman V; Cambau E; Tobelem G; Caen JP
    Presse Med; 1987 Jul 11-18; 16(27):1335. PubMed ID: 2956601
    [No Abstract]   [Full Text] [Related]  

  • 39. [Raynaud's phenomenon: effects of terazosin].
    Paterna S; Pinto A; Arrostuto A; Cannavò MG; Di Pasquale P; Cottone C; Licata G
    Minerva Cardioangiol; 1997 May; 45(5):215-21. PubMed ID: 9273472
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Usefulness of photoplethysmography and indexes of digital pressure in Raynaud phenomenon].
    Martínez S; Lozano P; Pallarés L; Juliá J; Artigues I; Plaza A; Rimbau EM; Corominas C; Gómez FT
    Med Clin (Barc); 1999 Sep; 113(9):327-30. PubMed ID: 10562927
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.